Home/Lateral Pharma/David Kenley

DK

David Kenley

CEO & Managing Director

Therapeutic Areas

Oncology Immunology Neurology Pain Infectious Disease

Lateral Pharma Pipeline

Drug	Indication	Phase
LAT9997	Neuropathic Pain	Phase 2 (next-gen)
LAT8881	Lumbar Radicular Pain (Sciatica)	Phase 1b
SCP Platform	Alzheimer's Disease / Neurodegeneration	Preclinical

Leadership Team at Lateral Pharma

Chief Scientific Officer

Chief Operating Officer

David Williamson

CFO & Company Secretary

View full Lateral Pharma profile